BCG, Calmette and Guérin's vaccine, was first used in 1921 to stem the spread of tuberculosis and has been in use ever since. Even though it is no longer mandatory in many countries, it is still widely administered in high TB burden countries around the world. In the last years, the efforts and investments have ramped up and there are promising new drugs and vaccines in the pipeline, but the gap in research & development (R&D) for TB investments is still very high. Considering the increasing threat of drug-resistant TB, an effective vaccine could be the most powerful tool to contain the spread and finally put an end to this ancient, but preventable disease

​